Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 155 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Accepts healthy volunteers

Slowly Digestible Carbohydrates for GLP-1 Secretion

NCT07572513
Conditions
Blood Glucose, GLP-1, Satiety, Second Meal Intake, Healthy Participant Study
Interventions
Maltodextrin (Placebo), Raw Corn Starch
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 45 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
West Lafayette, Indiana
Terminated Phase 3 Interventional Results available

High Dose Oxytocin Nasal Spray for Treatment of Tinnitus

NCT04210310
Conditions
Tinnitus
Interventions
Oxytocin, Placebo nasal spray
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Kidney Transplantation in Highly Sensitized Patients
Interventions
Imlifidase, PLEX, IVIg, Anti-CD20 antibodies, Eculizumab, Remain on wait list
Drug · Procedure · Other
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Conditions
Acute Mountain Sickness (AMS)
Interventions
T89 capsule, Placebo capsule
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
853 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Conditions
Healthy
Interventions
CHR-2797
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Evansville, Indiana
Conditions
Urinary Bladder Neoplasm
Interventions
Mitomycin C
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability Study of Quinine Sulfate Capsules Under Fasting and Fed Conditions

NCT00727272
Conditions
Healthy
Interventions
Quinine Sulfate Capsules 324 mg, Quinine Sulphate Tablets 300 mg
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions
CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone
Device · Drug
Lead sponsor
Diane George
Other
Eligibility
Up to 22 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
New York, New York
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual vs IV Atropine Bioavailability Study

NCT04290039
Conditions
Toxic Effect of Organophosphate and Carbamate Insecticides
Interventions
Atropine Sulfate Ophthalmic Solution, Atropine Sulphate Injection
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
High Point, North Carolina
Conditions
Clinical Pharmacology, Healthy Male Volunteer Study
Interventions
CC-122
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Daytona Beach, Florida
Completed Phase 1 Interventional Accepts healthy volunteers

Studying Different Formulations of SR13668 in Healthy Volunteers

NCT00896207
Conditions
Healthy, no Evidence of Disease
Interventions
Akt inhibitor SR13668
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 62 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Not listed Not applicable Interventional Accepts healthy volunteers

The Effect of a Multi-strain Probiotic on Acclimatization to High Altitude

NCT06552806
Conditions
Probiotics
Interventions
SLAB51
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Bishop, California • La Jolla, California
Conditions
Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
Interventions
IVIG (intravenous immunoglobulin), IVIG Placebo, Coordinated Care, Usual Care
Drug · Behavioral
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Musculoskeletal Effects of Bicarbonate

NCT01475214
Conditions
Muscle Loss, Fractures, Osteoporosis, Age Related, Fall Injury
Interventions
potassium bicarbonate, Inactive placebo capsule
Dietary Supplement · Other
Lead sponsor
Tufts University
Other
Eligibility
60 Years and older
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Colo-rectal Cancer
Interventions
C-Scan procedure
Device
Lead sponsor
Check-Cap Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Glioblastoma, Gliosarcoma
Interventions
Gleevec, RAD001, and Hydroxyurea
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Multiple Myeloma
Interventions
Cyclophosphamide, Etoposide, Melphalan, Carmustine, Filgrastim
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Conditions
Breast Cancer, Metastatic Cancer
Interventions
capecitabine, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, lapatinib ditosylate, paclitaxel, vinorelbine ditartrate, Trastuzumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Completed Not applicable Interventional

Imaging of Lymphatic Anomalies

NCT02744027
Conditions
Gorham Disease, Lymphatic Diseases, Lymphangiomatosis
Interventions
Dynamic Contrast Enhanced Magnetic Resonance Lymphangiography (DCMRL), Heavy Weighted T2 Imaging (T2W), Lymph Node Access
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
High Blood Pressure, Salt; Excess, Inflammation
Interventions
Furosemide 40 mg
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Formulation Bridging, Food Effect
Interventions
PBI-200 Tablet, PBI-200 Capsule, PBI-200 Suspension
Drug
Lead sponsor
Pyramid Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Springfield, Missouri
Conditions
Healthy Volunteers
Interventions
Sucralose, Aspartame, Acesulfame-Potassium, Control
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Keratolysis
Interventions
Riboflavin, Dextran, UVA Light Source
Drug · Device
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Conditions
HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma, Anal HSIL
Interventions
EXE-346 Probiotic, Placebo, Usual Care High Resolution Anoscopy (HRA)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California